文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

EMBRACE II研究:GEC-ESTRO妇科工作组与EMBRACE研究二十年演进成果与展望

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-01-11

本文回顾了GEC-ESTRO推荐发布十年来图像引导自适应近距离放疗(IGABT)在局部晚期宫颈癌中的推广与局限,并介绍EMBRACE II研究作为干预性观察性多中心研究,旨在通过先进靶区勾画、多参数剂量处方及先进EBRT和BT技术,基准化局部、淋巴结和全身控制并限制并发症,同时纳入转化研究。

要点

  • IGABT在局限且反应良好的肿瘤中局部控制优异。
  • 晚期肿瘤的局部区域控制、治疗相关并发症和远处转移是主要挑战。
  • EMBRACE II旨在验证先进EBRT和BT技术下的剂量与体积处方方案。

核心结论

  • IGABT已获广泛接受,但治疗实施和处方/分次方案差异大,需通过EMBRACE II以前瞻性剂量和体积处方方案基准化高水平的局部、淋巴结和全身控制并限制并发症。

研究设计与样本

  • EMBRACE II是一项干预性观察性多中心研究,采用先进靶区选择与勾画协议、多参数近距离放疗剂量处方协议(剂量约束临床验证)及先进EBRT(IMRT和IGRT)和BT(IC/IS)技术(临床验证),并纳入影像和组织生物标志物转化研究。

主要发现

  • RetroEMBRACE和EMBRACE I研究的 emerging evidence 表明临床结局与剂量处方和技术相关。
  • IGABT在局限且反应良好的肿瘤中局部控制优异。
  • 当前主要挑战包括晚期肿瘤的局部区域控制、治疗相关并发症和远处转移。

临床怎么用

  • 采用统一的靶区体积勾画和报告方法,但需注意治疗实施和处方/分次方案仍存在差异。
  • 基于证据的前瞻性剂量和体积处方协议,使用先进EBRT和BT技术以优化临床结局。

局限性

  • 原文未明确报告EMBRACE II研究的具体样本量、随访时间或统计效力等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The publication of the GEC-ESTRO recommendations one decade ago was a significant step forward for reaching international consensus on adaptive target definition and dose reporting in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Since then, IGABT has been spreading, particularly in Europe, North America and Asia, and the guidelines have proved their broad acceptance and applicability in clinical practice. However, a unified approach to volume contouring and reporting does not imply a unified administration of treatment, and currently both external beam radiotherapy (EBRT) and IGABT are delivered using a large variety of techniques and prescription/fractionation schedules. With IGABT, local control is excellent in limited and well-responding tumours. The major challenges are currently loco-regional control in advanced tumours, treatment-related morbidity, and distant metastatic disease. Emerging evidence from the RetroEMBRACE and EMBRACE I studies has demonstrated that clinical outcome is related to dose prescription and technique. The next logical step is to demonstrate excellent clinical outcome with the most advanced EBRT and brachytherapy techniques based on an evidence-based prospective dose and volume prescription protocol. The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state of the art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachytherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced EBRT (IMRT and IGRT) and brachytherapy (IC/IS) techniques (clinical validation). The study also incorporates translational research including imaging and tissue biomarkers.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pötter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018. PMID: 29594251. doi:10.1016/j.ctro.2018.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。